Insights & News in Healthcare Safety

Using Evidence to Facilitate Physician-Patient Conversations about GLP-1 RAs

Glucagon-like peptide receptor agonists (GLP-1 RAs) now available to promote weight loss—Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)—could potentially make much needed g...

Monitoring Patients Who Take GLP-1 RAs for Weight Loss – What Prescribers Should Know

Roughly one year after their introduction, Wegovy (semaglutide) and Zepbound (tirzepatide) continue to shake up the obesity treatment landscape in the United States. Uptake for these two glucagon-l...

Weighing the Evidence on New Weight Loss Drugs – Five Takeaways

The prevalence of overweight and obesity keeps worsening in America despite our enormous collective effort to lose weight. The U.S. Centers for Disease Control and Prevention estimates that overwei...

Bringing Everyone to the Table: Rapid Evidence Assessments Facilitate Meaningful Dialogue Across the Stakeholder Spectrum

In the last two decades, the number of commercially available genetic tests is thought to have increased by more than 5,000%—from approximately 1,500 to an estimated 100,000 or more. This number on...

Increased Payer Support for Telemedicine May Improve Maternal Health Outcomes and Lower Costs

When compared to ten other developed nations, the United States has the highest maternal death rate. Yet, according to a recent maternal mortality review committee report by the Centers for Disease...